miR-130a is upregulated in cisplatin-treated hepatocellular carcinoma cells to increase drug resistance [27], but downregulated in diabetic endothelial progenitor cells by targeting RUNX3 [28]. The gene discussed is RUNX3; the disease is hepatocellular carcinoma.